POSEIDA THERAPEUTICS INC (PSTX) Stock Price & Overview
NASDAQ:PSTX • US73730P1084
Current stock price
The current stock price of PSTX is 9.5 USD. Today PSTX is down by -0.63%. In the past month the price increased by 1.5%. In the past year, price increased by 211.48%.
PSTX Key Statistics
- Market Cap
- 925.965M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.63
- Dividend Yield
- N/A
PSTX Stock Performance
PSTX Stock Chart
PSTX Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to PSTX. When comparing the yearly performance of all stocks, PSTX is one of the better performing stocks in the market, outperforming 98.96% of all stocks.
PSTX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PSTX. Both the profitability and financial health of PSTX have multiple concerns.
PSTX Earnings
On November 7, 2024 PSTX reported an EPS of 0.21 and a revenue of 71.75M. The company beat EPS expectations (150.52% surprise) and beat revenue expectations (332.43% surprise).
PSTX Forecast & Estimates
10 analysts have analysed PSTX and the average price target is 9.18 USD. This implies a price decrease of -3.37% is expected in the next year compared to the current price of 9.5.
For the next year, analysts expect an EPS growth of 30.29% and a revenue growth 217.39% for PSTX
PSTX Groups
Sector & Classification
PSTX Financial Highlights
Over the last trailing twelve months PSTX reported a non-GAAP Earnings per Share(EPS) of -0.63. The EPS increased by 58.28% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -20.7% | ||
| ROE | -69.67% | ||
| Debt/Equity | 0.68 |
PSTX Ownership
PSTX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.81 | 391.561B | ||
| AMGN | AMGEN INC | 15.82 | 197.434B | ||
| GILD | GILEAD SCIENCES INC | 16.34 | 180.267B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.86 | 118.403B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.24 | 80.021B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.94 | 42.294B | ||
| INSM | INSMED INC | N/A | 31.169B | ||
| NTRA | NATERA INC | N/A | 28.017B | ||
| BIIB | BIOGEN INC | 11.52 | 26.895B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.08 | 23.418B | ||
| MRNA | MODERNA INC | N/A | 21.054B | ||
| EXAS | EXACT SCIENCES CORP | 341.95 | 19.824B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.619B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About PSTX
Company Profile
Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies and solid tumors. The company is headquartered in San Diego, California and currently employs 350 full-time employees. The company went IPO on 2020-07-10. Its pipeline includes allogeneic CAR-T cell therapy product candidates for both solid and liquid tumors, as well as in vivo gene therapy product candidates that address patient populations with high unmet medical need. Its approach to cell and gene therapies is based on its proprietary genetic editing platforms, including its non-viral piggyBac DNA Delivery System, Cas-CLOVER Site-Specific Gene Editing System, Booster Molecule and nanoparticle and hybrid gene delivery technologies, as well as in-house GMP cell therapy manufacturing. Its lead programs, including P-FVIII-101, a non-viral approach. Its product candidate P-BCMA-ALLO1 and P-BCMACD19-ALLO1 is developed for patients with multiple myeloma. P-BCMA-ALLO1 is in a Phase I trial, being developed for patients with relapsed/refractory multiple myeloma.
Company Info
IPO: 2020-07-10
POSEIDA THERAPEUTICS INC
9390 Towne Centre Drive, Suite 200
San Diego CALIFORNIA 92121 US
CEO: Eric Ostertag
Employees: 337
Phone: 18587793100
POSEIDA THERAPEUTICS INC / PSTX FAQ
What does POSEIDA THERAPEUTICS INC do?
Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies and solid tumors. The company is headquartered in San Diego, California and currently employs 350 full-time employees. The company went IPO on 2020-07-10. Its pipeline includes allogeneic CAR-T cell therapy product candidates for both solid and liquid tumors, as well as in vivo gene therapy product candidates that address patient populations with high unmet medical need. Its approach to cell and gene therapies is based on its proprietary genetic editing platforms, including its non-viral piggyBac DNA Delivery System, Cas-CLOVER Site-Specific Gene Editing System, Booster Molecule and nanoparticle and hybrid gene delivery technologies, as well as in-house GMP cell therapy manufacturing. Its lead programs, including P-FVIII-101, a non-viral approach. Its product candidate P-BCMA-ALLO1 and P-BCMACD19-ALLO1 is developed for patients with multiple myeloma. P-BCMA-ALLO1 is in a Phase I trial, being developed for patients with relapsed/refractory multiple myeloma.
Can you provide the latest stock price for POSEIDA THERAPEUTICS INC?
The current stock price of PSTX is 9.5 USD. The price decreased by -0.63% in the last trading session.
Does POSEIDA THERAPEUTICS INC pay dividends?
PSTX does not pay a dividend.
What is the ChartMill technical and fundamental rating of PSTX stock?
PSTX has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What do analysts say about POSEIDA THERAPEUTICS INC (PSTX) stock?
10 analysts have analysed PSTX and the average price target is 9.18 USD. This implies a price decrease of -3.37% is expected in the next year compared to the current price of 9.5.
What is the GICS sector and industry of PSTX stock?
POSEIDA THERAPEUTICS INC (PSTX) operates in the Health Care sector and the Biotechnology industry.
What is POSEIDA THERAPEUTICS INC worth?
POSEIDA THERAPEUTICS INC (PSTX) has a market capitalization of 925.97M USD. This makes PSTX a Small Cap stock.